Today: 21 May 2026
Sembcorp Industries stock slips to S$5.99 as Alinta deal nears key dates
11 January 2026
2 mins read

Sembcorp Industries stock slips to S$5.99 as Alinta deal nears key dates

Singapore, Jan 11, 2026, 15:33 SGT — Market closed.

  • Sembcorp Industries (SGX:U96) ended Friday at S$5.99, slipping 0.66%
  • Attention turns to the Alinta Energy acquisition: a circular is due mid-January, with a shareholder vote planned for the end of the month
  • On Friday, shares fluctuated from S$5.96 to S$6.03, shy of last week’s peak at S$6.10

Sembcorp Industries Ltd shares ended Friday down 0.66%, closing at S$5.99 after fluctuating between S$5.96 and S$6.03 during the day. Since the start of 2026, the stock has fallen roughly 1.5%, with around 4.5 million shares traded on Friday.

The Singapore market was closed over the weekend, leaving the stock stuck near S$6 as Monday’s session approaches. All eyes remain on a major corporate event that could change the narrative.

Sembcorp plans to acquire Australia’s Alinta Energy in a deal valued at A$6.5 billion (S$5.6 billion) on an enterprise value basis, according to a December investor presentation. The company intends to pay cash, backed by a fully committed A$6.5 billion bridge loan, which is a short-term financing tool usually replaced later with long-term funding. No equity fundraising is planned. Sembcorp aims to issue the circular and notice for an extraordinary general meeting by mid-January, with a shareholder vote expected by the end of January. Completion is targeted for the first half of 2026, pending regulatory approvals.

In a joint press release, Alex Tan, president and CEO for Renewables, East at Sembcorp, described the acquisition as a move to “strengthen” the group’s foothold in Australia and create a “scalable platform” for speeding up renewables and low-carbon growth. Alinta CEO Jeff Dimery referred to Sembcorp’s investment as “a vote of confidence” that would boost the scale of renewables and storage projects.

Sembcorp slipped late in the week while Singapore’s Straits Times Index crept up 0.1% to 4,744.66 on Friday. Regional markets mostly moved higher. Neil Wilson, UK investment strategist at Saxo Markets, warned the tariff debate might create “headline noise” but stressed: “Tariffs are not going anywhere.”

By Friday’s close, Sembcorp’s market cap stood near S$10.65 billion. The stock changed hands at a price-to-earnings ratio of about 10.7, based on figures from StockAnalysis.com.

Analysts have divided the Alinta deal into two parts: a near-term earnings boost and a longer-term carbon challenge. Luis Hilado from Citi Research called it “half-full” on earnings per share but “half-empty” when it comes to emissions. Meanwhile, CGS International’s Lim Siew Khee and Meghana Kande cautioned that the market might take a while to digest the increased coal exposure, The Business Times reported last December. The Business Times

The timetable remains uncertain. The deal requires shareholder approval, plus sign-offs from Australia’s Foreign Investment Review Board and the Australian Competition and Consumer Commission. On top of that, Sembcorp has to refinance the bridge facility on terms that make sense if borrowing costs stay elevated.

Traders are keeping an eye on whether the stock stays above Friday’s S$5.96 low and how it moves around S$6 in Monday’s session, Jan 12. If it climbs back toward last week’s S$6.10 high, the shares could shift from a fade to a wait-and-see stance.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Meritage Homes stock jumps 10% on Trump mortgage-bond order — what to watch next week
Previous Story

Meritage Homes stock jumps 10% on Trump mortgage-bond order — what to watch next week

BAT stock in focus: UBS sticks with Buy on British American Tobacco ahead of Feb results
Next Story

BAT stock in focus: UBS sticks with Buy on British American Tobacco ahead of Feb results

Go toTop